首页>
外国专利>
TESTS DEDICATED TO ONCOLOGY AND TO NEURO-ONCOLOGY
TESTS DEDICATED TO ONCOLOGY AND TO NEURO-ONCOLOGY
展开▼
机译：肿瘤和神经肿瘤学专用的测试
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to novel polypeptide, ribonucleotide and nucleotide sequences to be integrated into a novel test for screening for reinduction of the cell cycle targeting oncology, and to the use of some of these same functionalized sequences as an adjuvant treatment by molecular targeting. It is a major improvement without which the diagnosis and the pharmacodiagnostic test could only be partial. The consequence of this would be a less effective treatment with a narrower application according to the heterogeneity of cancers. It is therefore a diagnostic test and a prognostic test for various cancers. More particularly, the invention relates to the use of the genes or of the proteins of the LIV21 complex and also derivatives thereof as therapeutic tools and as diagnostic and prognostic markers for cancers. The invention therefore relates to the detection of the LIV21 gene or of the LIV21 protein with a kit comprising antibodies or probes specific for LIV21, but also the invention is the use of all the proliferation markers and transcription factors which play a role in the cancerization and, for some, neurodegeneration process. Therefore, the invention lies in the use of RT‑PCR and of quantitative PCR (Q PCR) twinned with the fabrication of diagnostic DNA chips, diagnostic protein chips and diagnostic antibody chips comprising the known antibodies for the various proteins of the protein complexes associated, according to the cell cycle phases, with the LIV21 complex, i.e., without restriction thereto: peptides of and antibodies for RBP2, E2F4, E2F1, SUMO, HDAC1, crb2, Int2, cmd2, cycE/cdk2, cdk1, CREB1 and p300, Rb, p107 and p130 of the pocket proteins family, but also NF-κB, cdc2A, mdm2, p21, p53, p65, BRCA1, TNFalpha and TGF beta. The novel sequences are the polynucleotide and polypeptide sequences of Liv21F, Liv21H, etc. (additional listing: SEQ ID No. 171 to 185 ...) and the sequences of corresponding genes, proteins and antibodies newly integrated into the pharmacodiagnostic biochips.
展开▼
机译：本发明涉及新的多肽，核糖核苷酸和核苷酸序列，其将被整合到用于筛选细胞周期靶向肿瘤学的新试验中，并且涉及这些相同功能化的序列中的一些作为通过分子靶向的佐剂治疗的用途。这是一个重大的进步，没有它，诊断和药物诊断测试只能是部分的。根据癌症的异质性，这将导致治疗效果较差，应用范围更窄。因此，它是针对各种癌症的诊断测试和预后测试。更具体地，本发明涉及LIV21复合物的基因或蛋白质及其衍生物作为癌症的治疗工具以及诊断和预后标志物的用途。因此，本发明涉及用包含对LIV21具有特异性的抗体或探针的试剂盒对LIV21基因或LIV21蛋白的检测，但是本发明还涉及在癌症的发生和发展中起作用的所有增殖标志物和转录因子的用途。 ，对于某些神经变性过程。因此，本发明在于RT-PCR和定量PCR（Q PCR）的结合，用于制造诊断DNA芯片，诊断蛋白芯片和诊断抗体芯片，其中包含已知抗体的相关蛋白复合物的各种蛋白质，根据细胞周期阶段，具有LIV21复合物，即但不限于：RBP2，E2F4，E2F1，SUMO，HDAC1，crb2，Int2，cmd2，cycE / cdk2，cdk1，CREB1和p300，Rb的肽和抗体，口袋蛋白家族的p107和p130，还有NF-κB，cdc2A，mdm2，p21，p53，p65，BRCA1，TNFalpha和TGF beta。新的序列是Liv21F，Liv21H等的多核苷酸和多肽序列（附加清单：SEQ ID No.171至185 ...）以及新整合到药物诊断生物芯片中的相应基因，蛋白质和抗体的序列。
展开▼
